These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
111 related items for PubMed ID: 850517
1. Changes in histologic and biochemical indexes of bone turnover after bilateral nephrectomy in patients on hemodialysis. Evidence for a possible role of endogenous calcitonin. Kanis JA, Earnshaw M, Heynen G, Ledingham JG, Oliver DO, Russell GG, Woods CG, Franchimont P, Gaspar S. N Engl J Med; 1977 May 12; 296(19):1073-9. PubMed ID: 850517 [Abstract] [Full Text] [Related]
2. Responses to salmon calcitonin in chronic renal failure: relation to histological and biochemical indices of bone turnover. Cundy T, Heynen G, Gaspar S, Earnshaw M, Bartlett M, Paton S, Kanis JA. Eur J Clin Invest; 1981 Jun 12; 11(3):177-84. PubMed ID: 6791936 [Abstract] [Full Text] [Related]
3. Evidence for a relationship between plasma immunoreactive calcitonin and bone disease in chronic renal failure. Kanis JA, Heynen G, Earnshaw M, Russell RG, Woods CG, Franchimont P, Gaspar S, Oliver D, Ledingham JG. Adv Exp Med Biol; 1977 Jun 12; 81():571-9. PubMed ID: 899941 [No Abstract] [Full Text] [Related]
4. Evidence that endogenous calcitonin protects against renal bone disease. Kanis JA, Oliver D, Ledingham JC, Russell RG. Lancet; 1976 Dec 18; 2(7999):1322-6. PubMed ID: 63802 [Abstract] [Full Text] [Related]
5. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy]. Bucciante G, Bernardi A, Biasia F, Milan G, Donato D. Minerva Med; 1985 Mar 10; 76(9-10):415-7. PubMed ID: 3982698 [No Abstract] [Full Text] [Related]
6. [Evaluation of terminal parathormone NH2 and COOH and plasma calcitonin in the blood of uremic patients under hemodialysis therapy]. Di Landro D, Zanatta GP, Simioni N, Pinzani A, Zotti D, Perin N, Bertoli M, Naso A, Ruffatti A, Gasparotto ML. Minerva Med; 1985 Mar 10; 76(9-10):419-23. PubMed ID: 3982699 [No Abstract] [Full Text] [Related]
17. Endogenous calcitonin does not protect against hyperparathyroid bone disease in renal failure. Malluche HH, Faugère MC, Ritz E, Caillens G, Wildberger D. Miner Electrolyte Metab; 1986 Aug 03; 12(2):113-8. PubMed ID: 3960014 [Abstract] [Full Text] [Related]
18. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function. Nielsen HE, Rømer FK, Melsen F, Christensen MS, Hansen HE. Clin Nephrol; 1980 Mar 03; 13(3):103-8. PubMed ID: 7379358 [Abstract] [Full Text] [Related]
19. Immunoreactive serum calcitonin and skeletal histology in chronic renal failure. Furlong T, Chan YL, Cornish C, McDowall D, Mahony J, Clifton-Bligh P. Nephron; 1991 Mar 03; 58(2):138-43. PubMed ID: 1865968 [Abstract] [Full Text] [Related]
20. [Acute effects of hemodialysis on circulating parathormone, osteocalcin and alkaline phosphatase in patients with chronic renal failure]. Broulík P, Hrubý M. Cas Lek Cesk; 1993 Nov 22; 132(22):681-3. PubMed ID: 8293434 [Abstract] [Full Text] [Related] Page: [Next] [New Search]